GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » Total Assets

Joinn Laboratories (China) Co (HKSE:06127) Total Assets : HK$10,032 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Joinn Laboratories (China) Co Total Assets?

Joinn Laboratories (China) Co's Total Assets for the quarter that ended in Dec. 2024 was HK$10,032 Mil.

Warning Sign:

If a company builds assets at 48.3% a year, faster than its revenue growth rate of 22.3% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Joinn Laboratories (China) Co's average Total Assets Growth Rate was 3.60% per year. During the past 3 years, the average Total Assets Growth Rate was 23.90% per year. During the past 5 years, the average Total Assets Growth Rate was 48.30% per year. During the past 10 years, the average Total Assets Growth Rate was 41.50% per year.

During the past 13 years, Joinn Laboratories (China) Co's highest 3-Year average Total Assets Growth Rate was 80.60%. The lowest was 7.30%. And the median was 30.75%.

Total Assets is connected with ROA %. Joinn Laboratories (China) Co's annualized ROA % for the quarter that ended in Dec. 2024 was 6.01%. Total Assets is also linked to Revenue through Asset Turnover. Joinn Laboratories (China) Co's Asset Turnover for the quarter that ended in Dec. 2024 was 0.07.


Joinn Laboratories (China) Co Total Assets Historical Data

The historical data trend for Joinn Laboratories (China) Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Total Assets Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,575.83 10,453.37 11,573.87 10,967.50 10,032.01

Joinn Laboratories (China) Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,967.50 10,573.25 10,400.78 10,487.67 10,032.01

Joinn Laboratories (China) Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Joinn Laboratories (China) Co's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=8625.923+1406.086
=10,032

Joinn Laboratories (China) Co's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (Q: Dec. 2024 )+Total Liabilities (Q: Dec. 2024 )
=8625.923+1406.086
=10,032

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Joinn Laboratories (China) Co  (HKSE:06127) Total Assets Explanation

Total Assets is connected with ROA %.

Joinn Laboratories (China) Co's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=616.612/( (10487.665+10032.01)/ 2 )
=616.612/10259.8375
=6.01 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Joinn Laboratories (China) Co's Asset Turnover for the quarter that ended in Dec. 2024 is

Asset Turnover
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=729.41/( (10487.665+10032.01)/ 2 )
=729.41/10259.8375
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Joinn Laboratories (China) Co Total Assets Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Joinn Laboratories (China) Co Business Description

Traded in Other Exchanges
Address
A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Executives
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Futu Trustee Limited 2301 Trustee
Ubs Group Ag 2201 Interest of corporation controlled by you
Aggregate Of Abrdn Plc Affiliated Investment Management Entities 2102 Investment manager
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co. 2502 Approved lending agent
Fidelity Funds 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Abrdn Asia Focus Plc 2101 Beneficial owner
Morgan Stanley 2201 Interest of corporation controlled by you
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Apg Asset Management N.v. 2101 Beneficial owner
Apg Groep N.v. 2101 Beneficial owner

Joinn Laboratories (China) Co Headlines

No Headlines